Ying Jiao Zhao1, Phern Chern Tor2,3,4, Ai Leng Khoo1, Monica Teng1, Boon Peng Lim1, Yee Ming Mok2. 1. Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore, Singapore. 2. Department of General Psychiatry 2, Institute of Mental Health, Mood Disorder Unit, Singapore, Singapore. 3. Duke-NUS Graduate Medical School, Singapore, Singapore. 4. National University of Singapore, Singapore, Singapore.
Abstract
BACKGROUND: Compared to electroconvulsive therapy (ECT), the cost-effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the management of treatment-resistant depression (TRD) remains unclear. OBJECTIVE/HYPOTHESIS: This study evaluated the cost-effectiveness of rTMS vs. ECT for TRD from Singapore societal perspective. METHODS: We constructed a Markov model to project the cost and benefit of rTMS compared with ECT over one year in patients with TRD. The relative treatment effects between rTMS and ECT were obtained from meta-analyses of published trials. The effectiveness and quality of life data for patients using ECT, resource use for TRD and their associated costs were derived from the national tertiary mental institution in Singapore. RESULTS: At one year, rTMS was cost-effective relative to ECT. The incremental cost-effectiveness ratio (ICER) associated with ECT was Singapore dollars (SGD) 311,024 per quality-adjusted life-year (QALY) gained. This exceeded the willingness-to-pay threshold of SGD 70,000 per QALY gained. A similar trend was observed for ICER per remission achieved (i.e., SGD 143,811 per remission achieved with ECT). In the subgroup analysis, rTMS was found to be less costly and more effective than ECT in nonpsychotic depressive patients. In the scenario analysis, ECT employed as an ambulatory service yielded a much smaller ICER (i.e., SGD 78,819 per QALY gained) compared to the standard inpatient setting. CONCLUSIONS: rTMS was a cost-effective treatment compared to ECT in TRD over one year. The cost-effectiveness of rTMS was attenuated when ECT was used in the outpatient setting.
BACKGROUND: Compared to electroconvulsive therapy (ECT), the cost-effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the management of treatment-resistant depression (TRD) remains unclear. OBJECTIVE/HYPOTHESIS: This study evaluated the cost-effectiveness of rTMS vs. ECT for TRD from Singapore societal perspective. METHODS: We constructed a Markov model to project the cost and benefit of rTMS compared with ECT over one year in patients with TRD. The relative treatment effects between rTMS and ECT were obtained from meta-analyses of published trials. The effectiveness and quality of life data for patients using ECT, resource use for TRD and their associated costs were derived from the national tertiary mental institution in Singapore. RESULTS: At one year, rTMS was cost-effective relative to ECT. The incremental cost-effectiveness ratio (ICER) associated with ECT was Singapore dollars (SGD) 311,024 per quality-adjusted life-year (QALY) gained. This exceeded the willingness-to-pay threshold of SGD 70,000 per QALY gained. A similar trend was observed for ICER per remission achieved (i.e., SGD 143,811 per remission achieved with ECT). In the subgroup analysis, rTMS was found to be less costly and more effective than ECT in nonpsychotic depressive patients. In the scenario analysis, ECT employed as an ambulatory service yielded a much smaller ICER (i.e., SGD 78,819 per QALY gained) compared to the standard inpatient setting. CONCLUSIONS: rTMS was a cost-effective treatment compared to ECT in TRD over one year. The cost-effectiveness of rTMS was attenuated when ECT was used in the outpatient setting.
Authors: Kyle P Fitzgibbon; Donna Plett; Brian C F Chan; Rebecca Hancock-Howard; Peter C Coyte; Daniel M Blumberger Journal: Can J Psychiatry Date: 2019-12-05 Impact factor: 4.356
Authors: Antal Zemplényi; Judit Józwiak-Hagymásy; Sándor Kovács; Dalma Erdősi; Imre Boncz; Tamás Tényi; Péter Osváth; Viktor Voros Journal: BMC Psychiatry Date: 2022-06-28 Impact factor: 4.144
Authors: Iris Dalhuisen; Filip Smit; Jan Spijker; Iris van Oostrom; Eric van Exel; Hans van Mierlo; Dieuwertje de Waardt; Martijn Arns; Indira Tendolkar; Philip van Eijndhoven Journal: BMC Psychiatry Date: 2022-02-05 Impact factor: 3.630